

Special Issue

Gold and Silver Complexes in the Treatment of Diseases 2.0

Message from the Guest Editor

At present, metal pharmaceuticals offer a new perspective in pharmacology and medicine. The growing development of so-called bioinorganic chemistry based on new drugs derived from metal complexes opens new possibilities in the treatment of diseases. In recent decades, gold complexes have been tested against HIV for the treatment of AIDS, acute forms of chronic asthma, and pemphigus (an autoimmune skin disease) and in the treatment of malaria, Chagas disease, and cancer. On the other hand, silver complexes have been used in the treatment of childhood blindness (ophthalmia neonatorum) and as antimicrobial agents for many years, and their antitumor potential is currently being studied. In recent years, the use of metal complexes as chemotherapeutic agents is gaining importance. Likewise, the use of nanoparticles as chemotherapeutic agents to transport metal complexes is beginning to be investigated. This Special Issue may publish original research papers and reviews on aspects related to gold and silver complexes in the treatment of diseases, highlighting the mechanism of action and targets involved in its therapeutic properties.

Guest Editor

Dr. María Jesús Rodríguez-Yoldi

Department of Pharmacology and Physiology, Legal and Forensic Medicine, Physiology Unit, Faculty of Veterinary Medicine, University of Zaragoza, 50013 Zaragoza, Spain

Deadline for manuscript submissions

closed (31 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/156145

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).